Exhibit 5.1
| | | | |
| | | | ![LOGO](https://capedge.com/proxy/8-K/0001193125-20-310704/g43336g1204121708734.jpg) |
| | | | Orrick, Herrington & Sutcliffe LLP |
| | | The Orrick Building 405 Howard Street |
| | | San Francisco, CA 94105-2669 |
| | | +1-415-773-5700 |
| | | orrick.com |
December 4, 2020
Twist Bioscience Corporation
681 Gateway Blvd.
South San Francisco, CA 94080
Re: 3,211,362 Shares of Common Stock of Twist Bioscience Corporation
Ladies and Gentlemen:
We have acted as counsel for Twist Bioscience Corporation, a Delaware corporation (the “Company”), in connection with the issuance and sale by the Company of up to 3,136,362 shares of common stock, par value $0.00001 per share, of the Company (the “Primary Shares”), and the sale of 75,000 shares of common stock, par value $0.00001 per share, of the Company held by certain selling stockholders of the Company (the “Secondary Shares” and together with the Primary Shares, the “Shares”), pursuant to an automatic shelf registration statement on Form S-3 (Registration Statement No. 333-238906) (the “Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Act”), including the prospectus dated June 3, 2020 included therein (the “Base Prospectus”), and the prospectus supplement dated December 2, 2020, filed with the Commission pursuant to Rule 424(b) of the rules and regulations of the Act (the “Prospectus Supplement”). The Base Prospectus and the Prospectus Supplement are collectively referred to as the “Prospectus.” The Shares are to be sold by the Company and the selling stockholders identified in the Prospectus in the manner described in the Registration Statement and the Prospectus. The Company is filing this opinion letter with the Commission on a Current Report on Form 8-K (the “Current Report”).
In connection with rendering this opinion, we have examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of (i) the Amended and Restated Certificate of Incorporation of the Company, as amended through the date hereof, (ii) the Amended and Restated Bylaws of the Company, as amended through the date hereof, (iii) certain resolutions of the Board of Directors of the Company and its Special Finance Committee relating to the issuance, sale and registration of the Shares, (iv) the Registration Statement, (v) the Prospectus, and (vi) such corporate records, agreements, documents and other instruments, and such certificates or comparable documents of public officials and of officers and representatives of the Company, and have made such inquiries of such officers and representatives, as we have deemed relevant and necessary or appropriate as a basis for the opinion set forth below.